Clinical significance of preoperative serum levels of CA 125 and TAG-72 in ovarian carcinoma

International Journal of Biological Markers

Volumn 12, Issue 3, 1997, Pages 112-117

  Gonzalez, A ^a   Vizoso, F ^b   Vazquez J ^b   Ruibal, A ^c   Balibrea, J L ^d  

^a HOSPITAL GENERAL DE SEGOVIA   (Spain)

^b Research Unit Foundation Hospital of Jove   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

CA 125; Ovarian carcinoma; TAG 72; Tumor markers

Indexed keywords

CA 125 ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC VALUE; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; MINIMAL RESIDUAL DISEASE; MUCINOUS CARCINOMA; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PREOPERATIVE EVALUATION; PROGNOSIS; PROSPECTIVE STUDY; TUMOR DIFFERENTIATION;

EID: 0031446837     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089701200305     Document Type: Article

References (23)

1. Bast RC, Freeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331-7.
2. Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types. Am J Clin Pathol 1983; 79: 98-104.
3. Bast RC, Klug TL, John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883-7.
4. Jaeger W, Baumbach H. It is not the pre- but the post-operative CA 125 level! J Tumor Marker Oncol 1989; 4: 182.
5. Jaeger W, Adam R, Wildt L, Lang N. Serum CA 125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer. Arch Gynecol Obstet 1988; 243: 91-9.
6. Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stase I epithelial ovarian cancer. Obstet Gynecol 1995; 98: 259-64.
7. Haslholzner U, Baumgartner L, Stieber P, et al. Clinical significance of the tumor markers CA 125 II and CA 72-4 in ovarian carcinoma. Int J Cancer 1996; 69: 29-334.
8. Colcher D, Horan Hand P, Nuti M, Scholm J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981; 78: 3119-203.
9. Gero EJ, Colcher D, Ferroni O, et al. CA 72-4 radioimmunoassay for the detection of TAG-72 carcinoma associated antigen in serum of patients. J Clin Lab Anat 1989; 3 (6): 360-9.
10. Ohuchi N, Takahashi K, Matoba N, et al. Comparison of serum assays for TAG-72, CA 19-9 and CEA in gastrointestinal carcinoma patients. Jpn J Clin Oncol 1989; 19: 242-8.
11. Filella X, Fuster J, Molina R, et al. TAG-72, CA 19.9 and CEA as tumor markers in gastric cancer. Acta Oncologica 1994; 33: 747-51.
12. Joypaul B, Browning M, Newman E, Byrne D, Cuschieri A. Comparison of serum CA 72-4 and CA 19-9 levels in gastric cancer patients and correlation with recurrence. Am J Surg 1995; 169: 595-9.
13. González A, Vizoso F, Allende MT, Sánchez MT, Balibrea JL, Ruibal A. Preoperative CEA and TAG-72 serum levels as prognostic indicators in resectable gastric carcinoma. Int J Biol Markers 1996; 11: 165-71.
14. Bayerl B, Meier W, Stieber P, Albiez M, Eiermann W, Fateh-Moghadam A. Significance of CA 72-4 in the diagnosis of ovarian cancer. In: Klapdor R, ed. Recent results in tumor therapy and diagnosis. Munich: Zuckschwedt-Verlag; 111-2.
15. Bast RC, Knauf S Jr, Epenetos A, et al. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer 1991; 68 (8): 1758-63.
16. Guadagni F, Marth C, Zeimet AG, et al. Evaluation of tumor-associated glycoprotein 72 (TAG 72) as a serum marker in patients with gynecologic diseases. Am J Obstet Gynecol 1994; 171: 1183-91.
17. Haslholzner U, Baumgartner L, Stieber P, Meier W, Hofmann K, Fateh-Moghadam A. Significance of tumor markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma. Anticancer Research 1994; 14: 2743-6.
18. International Federation of Gynecology and Obstetrics. Changes in definition of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987; 56: 263-4.
19. González A, Allende MT, Vizoso F, Ruibal A. Comportamiento de la glicoproteína asociada a tumores (TAG-72), definida por monoclonal B72.3 en el suero de pacientes con patologias no tumorales. Rev Clin Esp 1990; 186: 362-3.
20. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
21. Mantel N, Myers M. Problems of convergence of maximum likehood iterative procedures in multiparameter situations. J Am Statis Assoc 1971; 66: 484-91.
22. Cox DR. Regression models and life tables. J R Statis Soc B 1972; 34: 187-220.
23. Dixon WJ, ed. BMDP statistical software. Release 1990. Berkeley: University of California Press, 1986.